Shandong Boyuan Pharmaceutical&Chemical
301617
FORSTAR
835640
Cre8 Direct(Ningbo)Co.,Ltd.
300703
Minami Acoustics
301383
ASR Microelectronics
688220
(Q9)Sep 30, 2024 | (Q6)Jun 30, 2024 | (Q3)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q9)Sep 30, 2023 | (Q6)Jun 30, 2023 | (Q3)Mar 31, 2023 | (FY)Dec 31, 2022 | (Q9)Sep 30, 2022 | (Q6)Jun 30, 2022 | |
---|---|---|---|---|---|---|---|---|---|---|
Total operating revenue | -23.94%74.2M | -31.20%44.84M | -10.31%37.06M | 26.84%140.48M | 28.31%97.55M | 1.08%65.17M | -17.06%41.31M | -46.77%110.75M | -55.57%76.03M | -51.85%64.47M |
Operating revenue | -23.94%74.2M | -31.20%44.84M | -10.31%37.06M | 26.84%140.48M | 28.31%97.55M | 1.08%65.17M | -17.06%41.31M | -46.77%110.75M | -55.57%76.03M | -51.85%64.47M |
Total operating cost | -8.94%65.87M | -3.06%43.39M | 15.03%26.65M | 31.08%105.37M | 26.35%72.33M | 10.68%44.76M | -4.20%23.17M | -13.08%80.38M | -19.76%57.25M | -22.52%40.44M |
Operating cost | -23.40%27.62M | -32.14%16.28M | -10.86%13.51M | 41.21%57.39M | 41.29%36.06M | 19.57%23.99M | 8.16%15.16M | -27.45%40.64M | -41.56%25.52M | -40.62%20.06M |
Operating tax surcharges | -25.58%1.07M | -14.04%983.28K | 0.27%485.85K | 122.33%2.28M | 173.00%1.44M | 119.83%1.14M | 1,719.84%484.52K | -12.92%1.03M | -17.19%528.36K | -16.09%520.34K |
Operating expense | 20.08%5.01M | 23.55%3.49M | 20.55%1.42M | 9.35%5.93M | -3.40%4.17M | 1.01%2.83M | -18.21%1.17M | 19.65%5.43M | 51.80%4.32M | 59.72%2.8M |
Administration expense | -14.83%16.2M | 7.15%12.14M | 35.58%6.32M | 20.48%24.78M | 27.61%19.02M | 10.42%11.33M | -19.98%4.66M | 11.27%20.57M | 4.45%14.9M | 16.83%10.27M |
Financial expense | 67.88%-283.16K | 64.47%-238.45K | 62.95%-123.13K | 26.25%-1.06M | 12.10%-881.66K | 7.38%-671.05K | 30.24%-332.35K | -377.14%-1.43M | -233.96%-1M | -194.31%-724.52K |
-Interest expense (Financial expense) | ---- | ---- | ---- | ---- | ---- | ---- | ---- | -94.86%72.5K | -84.72%165.26K | -77.17%165.26K |
-Interest Income (Financial expense) | 58.79%-366.07K | 64.13%-242.19K | 62.51%-125.38K | 29.98%-1.07M | 25.10%-888.23K | 24.51%-675.26K | 39.43%-334.4K | -58.13%-1.53M | -195.68%-1.19M | -4,293.96%-894.52K |
Research and development | 29.75%16.25M | 74.90%10.73M | 149.22%5.04M | 13.32%16.04M | -3.53%12.52M | -18.38%6.13M | -39.77%2.02M | 20.53%14.16M | 41.55%12.98M | 16.01%7.51M |
Credit Impairment Loss | -159.12%-8.4M | -56.71%-6.57M | -59.73%-2.7M | -3,021.36%-3.45M | -524.52%-3.24M | -524.50%-4.19M | -3.14%-1.69M | 107.65%118.04K | 86.46%-518.85K | 71.62%-670.89K |
Asset Impairment Loss | -2,156.84%-4.23M | -1,595.83%-1.55M | -656.01%-691.5K | -517.09%-1.99M | ---187.22K | ---91.47K | ---91.47K | -102.92%-323.18K | ---- | ---- |
Other net revenue | ||||||||||
Invest income | -18.56%7.11M | -7.56%5.08M | -19.98%2.59M | -20.73%12.12M | -27.76%8.73M | -22.52%5.49M | 2.48%3.24M | 338.96%15.29M | 3,287.81%12.09M | 4,449.08%7.09M |
Asset deal income | ---- | ---- | ---- | -103.03%-1.89K | ---- | ---- | ---- | -16.64%62.39K | -20.65%59.39K | -20.65%59.39K |
Other revenue | 9.20%2.31M | 10.05%1.74M | -11.41%972.58K | 74.66%5.69M | -18.46%2.11M | 48.38%1.58M | 218.37%1.1M | -70.55%3.26M | -58.46%2.59M | -82.10%1.06M |
Operating profit | -84.29%5.13M | -99.36%147.43K | -48.92%10.57M | -2.66%47.48M | -1.09%32.64M | -26.52%23.2M | -24.88%20.7M | -62.04%48.77M | -67.83%33M | -63.05%31.58M |
Add:Non operating Income | -99.49%47.61K | -99.90%8.47K | -98.78%167.27 | 319.42%9.31M | 321.47%9.3M | 315.99%8.33M | 824.34%13.74K | -52.69%2.22M | 10.16%2.21M | -0.04%2M |
Less:Non operating expense | 923.04%122.04K | -81.61%2.14K | -95.03%561.9 | -65.98%39.59K | -89.88%11.93K | -31.64%11.62K | -30.44%11.32K | 137.78%116.38K | 3,826.23%117.86K | 466.13%16.99K |
Total profit | -87.95%5.05M | -99.51%153.77K | -48.92%10.57M | 11.54%56.75M | 19.50%41.93M | -6.09%31.52M | -24.83%20.7M | -61.78%50.88M | -66.45%35.09M | -61.63%33.56M |
Less:Income tax cost | -127.04%-1.25M | -130.97%-1.23M | -68.53%1M | 18.29%7.04M | -13.65%4.64M | -24.13%3.99M | -23.70%3.19M | -67.97%5.96M | -64.42%5.37M | -59.30%5.26M |
Net profit | -83.09%6.31M | -94.96%1.39M | -45.36%9.57M | 10.64%49.7M | 25.49%37.29M | -2.74%27.53M | -25.03%17.51M | -60.78%44.92M | -66.79%29.72M | -62.03%28.31M |
Net profit from continuing operation | -83.09%6.31M | -94.96%1.39M | -45.36%9.57M | 10.64%49.7M | 25.49%37.29M | -2.74%27.53M | -25.03%17.51M | -60.78%44.92M | -66.79%29.72M | -62.03%28.31M |
Net profit of parent company owners | -83.09%6.31M | -94.96%1.39M | -45.36%9.57M | 10.64%49.7M | 25.49%37.29M | -2.74%27.53M | -25.03%17.51M | -60.78%44.92M | -66.79%29.72M | -62.03%28.31M |
Earning per share | ||||||||||
Basic earning per share | -87.06%0.0614 | -94.95%0.0177 | -45.31%0.1218 | 12.52%0.6325 | 27.76%0.4745 | -0.99%0.3503 | -23.73%0.2227 | -66.47%0.5621 | -73.25%0.3714 | -71.53%0.3538 |
Diluted earning per share | -87.06%0.0614 | -94.95%0.0177 | -45.31%0.1218 | 12.52%0.6325 | 27.76%0.4745 | -0.99%0.3503 | -23.73%0.2227 | -66.47%0.5621 | -73.25%0.3714 | -71.53%0.3538 |
Other composite income | ||||||||||
Total composite income | -83.09%6.31M | -94.96%1.39M | -45.36%9.57M | 10.64%49.7M | 25.49%37.29M | -2.74%27.53M | -25.03%17.51M | -60.78%44.92M | -66.79%29.72M | -62.03%28.31M |
Total composite income of parent company owners | -83.09%6.31M | -94.96%1.39M | -45.36%9.57M | 10.64%49.7M | 25.49%37.29M | -2.74%27.53M | -25.03%17.51M | -60.78%44.92M | -66.79%29.72M | -62.03%28.31M |
Currency Unit | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY |
Accounting Standards | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) |
Audit Opinions | -- | -- | -- | Unqualified opinion | -- | -- | -- | Unqualified opinion | -- | -- |
Auditor | -- | -- | -- | Sichuan Huaxin (Group) Accounting Firm (Special General Partnership) | -- | -- | -- | Sichuan Huaxin (Group) Accounting Firm (Special General Partnership) | -- | -- |
FY: Financial Year. Refers to the 10-K file disclosed by the listed company to the SEC.
Q: Quarter. Refers to the 10-Q file disclosed by the listed company to the SEC. Q1, Q2, Q3, and Q4 are quarterly reports each with a span of 3 months; Q6 and Q9 are cumulative reports, with Q6 including 6 months and Q9 9 months.